Anti-Müllerian Hormone and Embryo Aneuploidy | Clinical Trial | StuddyBuddy@endsection Anti-Müllerian Hormone and Embryo Aneuploidy
Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05723016

Anti-Müllerian Hormone and Embryo Aneuploidy

Conditions: Infertility, Aneuploidy

Sex: Female
Enrollment: 300
Sponsor: Clinica de la Mujer Medicina Reproductiva, Chile

Location: Chile

Summary

The goal of this observational study is to determine is there an association between the rates of aneuploidy and the different ranges of serum Antimullerian hormone (AMH) levels.Retrospective, single-centre study of patients undergoing IVF and preimplantation genetic testing with aneuploidy at the blastocyst stage between January 2018 and December 2022.

Eligibility Criteria

Inclusion Criteria:All started cycles planned to be followed by preimplantation genetic testing for aneuploidies (PGT-A). PGT-A is proposed to the couples for the following reasons: advanced maternal age, recurrent miscarriage, repeated implantation failure or severe male infertility factor; it is also offered to all patients with a good prognosis who desired information regarding the ploidy status of their embryos.Exclusion Criteria:Data from oocyte donation cycles

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05723016). StuddyBuddy aggregates publicly available trial information.